Pharmacy of the World
Trust travels far. Indian medicines today reach over 200 countries — trusted in remote rural clinics and deployed in humanitarian health crises around the world. As the #1 exporter of vaccines globally and the third-largest pharmaceutical producer by volume, India plays a decisive role in global public health. With $30.5 billion in pharmaceutical exports in FY24 and a dominant share in generics to markets like the US and UK, India’s pharmaceutical sector is both vast and vital.
For over 25 years, IPA has supported this global leadership — facilitating bilateral agreements, engaging with regulators and trade bodies, and strengthening India’s reputation for high-quality, affordable, and resilient pharmaceutical supply.
200+ Countries Served
With 30+ countries reliant on Indian APIs & finished drugs
#1 in Vaccines
Over 60% of global vaccines are Indian-made
$30.5 B in Exports
FY 2024–25 pharma exports — up 9.4% YoY
Expanding Access, Shaping Policy
From trade negotiations to regulatory alignment, IPA champions India’s pharmaceutical leadership on the world stage — driving access, trust, and collaboration across borders. As global health priorities evolve and the geopolitical centre of gravity tilts towards the Global South, India’s role as a trusted, scalable, and strategic supplier is more critical than ever.
Public Health at the Core of TRIPS
From Section 3(d) to global Trade-Related Aspects of Intellectual Property Rights (TRIPS) negotiations, IPA champions policies that support innovation without monopoly, ensuring affordable access to medicines remains protected.
Learn more: TRIPS and Public Health SafeguardsGlobal Generics & Biosimilar Leadership
IPA holds leadership roles in the International Generic and Biosimilar Medicines Association, shaping global discussions through the CEO Advisory and Management Committees. Highlights include the Global Generics Vision Report and contributions to USTR-301 and market access dialogue.
Read: Global Generics & Biosimilars Vision 2030
Global Partnerships
As the world recalibrates its healthcare strategies, India’s pharmaceutical alliances have emerged as both practical and strategic. IPA plays a catalytic role in these collaborations — not just as a trade representative, but as a trust builder in a shifting global health order.
India–US Medicines Partnership
For decades, Indian pharmaceutical companies have been trusted partners to America — supplying nearly 50% of all U.S. generic prescriptions and delivering $219 billion in savings to the U.S. healthcare system in 2022 alone, and over $1.3 trillion in the past decade. Through CEO-led delegations and engagement with the US FDA, IPA works to build regulatory trust, promote affordability, and strengthen medicine supply chains between the two nations.
Read the ReportBilateral & Multilateral Trade Engagement
IPA supports India’s pharmaceutical trade diplomacy with partners, including Australia, the UAE, EFTA, the EU, and the UK, advocating for frameworks that balance market access and public health priorities.
Explore India’s Pharma Trade Partnerships
Research, Reports & Policy Impact
Evidence-led advocacy for global trust.
Reflecting IPA’s commitment to transparency, data integrity, and thought leadership, IPA publishes strategic insights on key international issues, including:
- De-risking the U.S. Supply Chain
- Market Access Barriers
- USTR-301 Policy Submissions
The World Is Changing — So Is Indian Pharma.
Today’s healthcare and trade ecosystems are being reshaped — and India must lead from the front.
Blockbuster Opportunities
With 55+ blockbuster drugs going off-patent by 2030, India has a unique opportunity to deliver high-quality, affordable alternatives. IPA’s vision report outlines the strategy for global leadership.
Read: Global Generics & Biosimilars ReportThe World’s Pharmacy, The World’s Partner
HIV Drugs at 1/100th the Cost
Indian generics helped Brazil reduce HIV treatment costs dramatically — enabling the government to expand coverage for vulnerable populations.
Fighting Malaria with the Global Fund
IPA members have supplied high-quality ACTs and diagnostics across Sub-Saharan Africa under WHO-led and Global Fund campaigns.
Emergency Supply During Crisis
In 2022, Indian pharmaceutical firms were among the first to supply essential medicines and humanitarian kits during the Ukrainian conflict.